Pioneering new therapeutics
for high unmet medical needs

About Us

Our Mission
MT-act is a preclinical stage spin-off company, stemming from a CNRS research institute dedicated to cutting-edge biological sciences and understanding of human pathophysiology.

We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the microtubular network. Microtubules are the largest cytoskeletal elements and provide structural support to human cells in addition to accommodating the intracellular trafficking system employed to deliver essential cargoes. Numerous human pathologies have specifically been linked to dysregulation of microtubule properties and this is where we act.

The company roots on a unique platform technology providing chemical versatility to develop first-in-class compounds that serve drug development programs. Employing a knowledge-based view, MT-act develops drug candidates to correct microtubule dysfunctions. The choice of the targeted mode of action is highly differentiated.

Origin and Innovation
MT-act is committed to transform the growing body of research and recent breakthrough discoveries in the Tubulin Code field, into new and life-altering medicines. Based on breakthrough discoveries, proprietary technologies and unique expertise, MT-act screens, validates and isolates first-in-class compounds with a unique microtubule-focused mode-of-action (MoA). MT-act pre-clinically develops transformative therapies that act and restore microtubular dysfunction in various human pathologies with high-unmet medical need.

Based on breakthrough discoveries, proprietary technologies and unique expertise, MT-act screens, validates and isolates the best compounds with a unique microtubule-focused mode-of-action (MoA). MT-act pre-clinically develops compounds to act and restore microtubule function (MT).

Solution

Unique approach and new mechanism of action (MoA). Proprietary biochemical assay for compound screening.

Research

First-in-class compounds that target a microtubule-focused mechanism of action (MoA).

Unmet medical need

A panoply of pathologies with high unmet medical needs related to aberrant tubulin modifications have been identified.

Experience

The team gathers business professionals and experts in the biology of the therapeutic targets. We are advised by key opinion leaders in pharmaceutical sciences, chemistry and medicine.

Our Partners

Send us a message

Contact Us